Diadema Partners LP holds a focused book of 86 stocks worth $242.2M as of Q1 2026 (disclosed May 15, 2026, a ~45-day 13F lag). This quarter they opened Bridgebio Pharma Inc and trimmed Johnson & Johnson. Their largest long position is Bridgebio Pharma Inc at 8% of the equity book. They also disclosed $137.3M in put options (a bearish bet) and $208.2M in call options (bullish), shown separately below and excluded from the equity book.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/2026172/holdings"
Use Arkolith to show DIADEMA PARTNERS LP's latest holdings, largest changes, and filing provenance.
Top-heavy: focused book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
87% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Bridgebio Pharma Inc NOTE 1.750% 3/0 | $18.6M | 250.0K | 7.7% | ▲New New position | |
| 2 | Viking Therapeutics Inc COM | $17.1M | 525.2K | 7.1% | ▲+56% Added · +188K sh | |
| 3 | United Therapeutics Corp Del COM | $16.2M | 27.3K | 6.7% | ▲+173% Added · +17K sh | |
| 4 | Johnson & Johnson COM | $13.1M | 53.8K | 5.4% | ▼−19% Reduced · −13K sh | |
| 5 | Cogent Biosciences Inc COM | $12.4M | 322.8K | 5.1% | ▲+145% Added · +191K sh | |
| 6 | Jazz Pharmaceuticals PLC SHS USD | $10.4M | 54.8K | 4.3% | ▲New New position | |
| 7 | Terns Pharmaceuticals Inc COM | $9.6M | 181.8K | 4.0% | ▼−47% Reduced · −164K sh | |
| 8 | Biomarin Pharmaceutical Inc COM | $8.4M | 148.2K | 3.5% | ▲+1.3% Added · +2K sh | |
| 9 | Abivax Sa SPONSORED ADS | $8.2M | 75.9K | 3.4% | ▲+0.4% Added · +300 sh | |
| 10 | Revolution Medicines Inc COM | $7.9M | 80.9K | 3.2% | ▲+118% Added · +44K sh | |
| 11 | Kodiak Sciences Inc COM | $7.4M | 193.0K | 3.0% | ▲New New position | |
| 12 | Incyte Corp COM | $7.3M | 78.0K | 3.0% | ▲New New position | |
| 13 | TG Therapeutics Inc COM | $6.9M | 206.9K | 2.8% | ▲+68% Added · +84K sh | |
| 14 | Bridgebio Pharma Inc COM | $6.3M | 85.3K | 2.6% | ▲+22% Added · +15K sh | |
| 15 | Immunocore Hldgs PLC ADS | $5.8M | 193.2K | 2.4% | ▲+175% Added · +123K sh | |
| 16 | Eli Lilly & Co COM | $5.5M | 6.0K | 2.3% | ▲+200% Added · +4K sh | |
| 17 | Abbvie Inc COM | $5.2M | 24.1K | 2.2% | ▲New New position | |
| 18 | Arcus Biosciences Inc COM | $5.1M | 238.1K | 2.1% | ▲New New position | |
| 19 | Corbus Pharmaceuticals Hldgs COM NEW | $4.1M | 440.0K | 1.7% | ▲New New position | |
| 20 | Corvus Pharmaceuticals Inc COM | $3.6M | 244.8K | 1.5% | ▲New New position | |
| 21 | Zymeworks Inc COM | $3.6M | 142.1K | 1.5% | ▲New New position | |
| 22 | Structure Therapeutics Inc SPONSORED ADS | $3.5M | 72.2K | 1.4% | ▲New New position | |
| 23 | Monte Rosa Therapeutics Inc COM | $3.1M | 187.3K | 1.3% | ▲+201% Added · +125K sh | |
| 24 | Tenax Therapeutics Inc COM NEW | $2.9M | 179.7K | 1.2% | ▼−26% Reduced · −63K sh | |
| 25 | Harmony Biosciences Hldgs In COM | $2.6M | 92.9K | 1.1% | ▲12× Added · +85K sh | |
| 26 | Capricor Therapeutics Inc COM NEW | $2.4M | 78.9K | 1.0% | ▼−50% Reduced · −79K sh | |
| 27 | Eyepoint Inc COM NEW | $2.3M | 178.5K | 1.0% | ▲New New position | |
| 28 | Bicycle Therapeutics PLC SPONSORED ADS | $2.2M | 476.4K | 0.9% | ▲New New position | |
| 29 | Indivior Pharmaceuticals Inc COM | $2.2M | 71.4K | 0.9% | ▲New New position | |
| 30 | Climb Bio Inc COM | $2.0M | 286.1K | 0.8% | ▲New New position | |
| 31 | Inventiva Sa ADS | $1.9M | 352.4K | 0.8% | ▲+5.4% Added · +18K sh | |
| 32 | Shattuck Labs Inc COM | $1.9M | 293.7K | 0.8% | ▲New New position | |
| 33 | Tarsus Pharmaceuticals Inc COM | $1.8M | 25.9K | 0.8% | ▲New New position | |
| 34 | Alkermes PLC SHS | $1.8M | 50.0K | 0.7% | ▲New New position | |
| 35 | Macrogenics Inc COM | $1.7M | 600.0K | 0.7% | ▲New New position | |
| 36 | Vertex Pharmaceuticals Inc COM | $1.7M | 3.8K | 0.7% | ▼−62% Reduced · −6K sh | |
| 37 | Voyager Therapeutics Inc COM | $1.6M | 423.6K | 0.7% | ▲New New position | |
| 38 | Vaxcyte Inc COM | $1.5M | 25.1K | 0.6% | ▲+9.1% Added · +2K sh | |
| 39 | Relmada Therapeutics Inc COM | $1.4M | 200.8K | 0.6% | ▼−48% Reduced · −189K sh | |
| 40 | Bioage Labs Inc COM | $1.0M | 60.0K | 0.4% | ▼−78% Reduced · −211K sh | |
| 41 | Inovio Pharmaceuticals Inc COM SHS | $979K | 562.7K | 0.4% | ▲+5.4% Added · +29K sh | |
| 42 | Aytu Biopharma Inc COM | $964K | 353.1K | 0.4% | ▲+15% Added · +47K sh | |
| 43 | Equillium Inc COM | $868K | 433.8K | 0.4% | ▲+25% Added · +86K sh | |
| 44 | Dianthus Therapeutics Inc COM | $839K | 10.0K | 0.3% | ▲New New position | |
| 45 | Pharvaris N V COM | $828K | 29.3K | 0.3% | ▲New New position | |
| 46 | Enanta Pharmaceuticals Inc COM | $820K | 65.0K | 0.3% | ▼−0.3% Reduced · −186 sh | |
| 47 | Replimune Group Inc COM | $770K | 100.7K | 0.3% | ▼−56% Reduced · −130K sh | |
| 48 | Xeris Biopharma Holdings Inc COM | $770K | 132.7K | 0.3% | ▼−22% Reduced · −38K sh | |
| 49 | Larimar Therapeutics Inc COM | $750K | 166.6K | 0.3% | ▲New New position | |
| 50 | Annexon Inc COM | $736K | 132.9K | 0.3% | ▼−62% Reduced · −217K sh |
Put / call positions from the 13F — totals include every disclosed option leg
| Type | Underlying | Notional value | Underlying shares |
|---|---|---|---|
| CALL · bullish | VERTEX PHARMACEUTICALS INCVRTX | $41.6M | 93K |
| CALL · bullish | LIQUIDIA CORPLQDA | $25.0M | 662K |
| CALL · bullish | UNITED THERAPEUTICS CORPUTHR | $23.8M | 40K |
| CALL · bullish | VIKING THERAPEUTICS INCVKTX | $21.5M | 659K |
| PUT · bearish | CAPRICOR THERAPEUTICS INCCAPR | $19.0M | 623K |
| CALL · bullish | APOGEE THERAPEUTICS INCAPGE | $18.7M | 223K |
| PUT · bearish | CYTOKINETICS INCCYTK | $13.2M | 200K |
| PUT · bearish | REVOLUTION MEDICINES INCRVMD | $12.2M | 126K |
| PUT · bearish | MERCK & CO. INC.MRK | $12.0M | 100K |
| PUT · bearish | UNITED THERAPEUTICS CORPUTHR | $11.9M | 20K |
| CALL · bullish | ABIVAX SA-ADRABVX | $11.1M | 100K |
| PUT · bearish | ABIVAX SA-ADRABVX | $11.1M | 100K |
| CALL · bullish | CAPRICOR THERAPEUTICS INCCAPR | $10.0M | 329K |
| PUT · bearish | INCYTE CORPINCY | $9.9M | 105K |
| PUT · bearish | KODIAK SCIENCES INCKOD | $9.4M | 247K |
| PUT · bearish | ROIVANT SCIENCES LTDROIV | $9.3M | 336K |
| PUT · bearish | MODERNA INCMRNA | $8.1M | 159K |
| CALL · bullish | EDGEWISE THERAPEUTICS INCEWTX | $6.7M | 213K |
| CALL · bullish | CORCEPT THERAPEUTICS INCCORT | $6.4M | 159K |
| PUT · bearish | STRUCTURE THERAPEUTICS INCGPCR | $6.1M | 128K |
| CALL · bullish | CRISPR THERAPEUTICS AGCRSP | $5.1M | 106K |
| PUT · bearish | UNIQURE NVQURE | $4.9M | 299K |
| CALL · bullish | UNIQURE NVQURE | $4.1M | 250K |
| PUT · bearish | REPLIMUNE GROUP INCREPL | $3.5M | 460K |
| CALL · bullish | CYTOKINETICS INCCYTK | $3.3M | 50K |
13F filers disclose option positions at the market value of the underlying the contracts reference, not the premium paid. A put is a bearish bet (it gains if the stock falls); a call is bullish. “Underlying shares” is the share count the contracts control, not a share holding. These legs are excluded from the equity book, weighting, concentration and sector figures above. Showing the largest 25 of 58 option legs.
As-of date vs the date the SEC received each filing
Holdings from SEC EDGAR 13F-HR filings, updated quarterly ~45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.